Analyzing the Role of Second-Line Ramucirumab in HCC
Ghassan K. Abou-Alfa, MD, discusses the current role for ramucirumab for the treatment of patients with hepatocellular carcinoma in the second-line setting.
Ghassan K. Abou-Alfa, MD, from the Memorial Sloan Kettering Cancer Center, discusses the current role for ramucirumab (Cyramza) for the treatment of patients with hepatocellular carcinoma (HCC) in the second-line setting.
In May 2019, theFDA granted approval to ramucirumab monotherapy for the treatment of patients with HCC who have an alpha-fetoprotein (AFP) level of ≥400 ng/mLand have been previously treated with sorafenib (Nexavar), based on data from the phase III REACH-2 trial. For now, this agent is only applicable to patients with an elevated AFP above 400, says Abou-Alfa, but elevated AFP levels remain a complex piece of information.
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
